🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Good stuff in here — I’m happy to have made a small contribution along the way. Link to report in final tweet of thread.

Excellent call to action re: addiction & biotech. Yes, drugs meant to affect behavior are challenging on all levels...all the more reasons to improve how they are designed and distributed today. ~750k deaths/year in the U.S. is staggering.

An innovation agenda for addiction, from CASPR IFP recursiveadaptation.com/p/an-innovatio…

Willy Nicholas Reville CASPR omfg I was just thinking to myself that I wanted to read something like this

A new nonprofit, CASPR (the Center for Addiction Science, Policy, and Research), is out with a sweeping policy agenda. (Consider the vast serious costs of the opioid crisis, times other substances.) All the info: recursiveadaptation.com/p/an-innovatio…

Our addiction predictions for 2025 and beyond: GLP-1 micro-dosing, non-opioid painkillers, alcohol trends, and more. recursiveadaptation.com/p/addiction-pr…

fas.org/publication/in…

"The Harm Reduction Promise of GLP-1s" CASPR Cofounder Nicholas Reville will be speaking at this event at Cato Institute on January 24. Please join us, in person or online. Registration is open. cato.org/events/harm-re…

It's very cool to see what CASPR is doing to spur innovation in the treatment of substance use disorders (e.g. GLP-1s). Check out some of their recent activities: recursiveadaptation.com/p/glp-1-event-…

CASPR Executive Director Nicholas Reville is on the Chris Hayes podcast today, hope you will listen! iOS: podcasts.apple.com/us/podcast/why… Spotify: open.spotify.com/episode/1pln27…

Please join us in person or online at this free Cato Institute event on Jan 24th. Nicholas Reville will be speaking about GLP-1s and innovation in addiction medicine, moderated by Dr. Jeffrey Singer, Jeffrey A. Singer. Register free here: cato.org/events/harm-re…

GLP-1s and addiction, "cravings are a more specific and more helpful way to look at what’s happening in addiction. And if you reduce those cravings, you can give people a chance, some space in their lives to address the other patterns, the other circumstances that have led them

*starting in 10 minutes* join the livestream to hear Nicholas Reville speak about the transformative implications of GLP-1s for addiction treatment, and policies to improve affordability and access for those who need them.

Tune in to our policy forum "The Harm Reduction Promise of GLP-1s" with Michael F. Cannon 🇮🇪🇺🇸, Jeffrey A. Singer, Sally Satel and Nicholas Reville. x.com/i/broadcasts/1…

youtu.be/RLGLEaAhVJQ

CASPR, and our research on GLP-1s for opioid use disorder, got a shout-out in this fascinating convo between Naval and Chris Williamson . They discussed the ideas that will shape the future, and call out GLP-1s to treat addiction. 5:30 for Naval's shout-out!